TY  - JOUR
AU  - Salvador Bofill, Javier
AU  - Moreno Anton, Fernando
AU  - Rodriguez Sanchez, Cesar Augusto
AU  - Galve Calvo, Elena
AU  - Hernando Melia, Cristina
AU  - Ciruelos Gil, Eva Maria
AU  - Vidal, Maria
AU  - Jiménez-Rodriguez, Begoña
AU  - De la Cruz Merino, Luis
AU  - Martínez Jañez, Noelia
AU  - Villanueva Vazquez, Rafael
AU  - de Toro Salas, Ruben
AU  - Anton Torres, Antonio
AU  - Alvarez Lopez, Isabel Manuela
AU  - Gavila Gregori, Joaquin
AU  - Quiroga Garcia, Vanesa
AU  - Vicente Rubio, Elena
AU  - De la Haba-Rodriguez, Juan
AU  - Gonzalez-Santiago, Santiago
AU  - Diaz Fernandez, Nieves
AU  - Barnadas Molins, Agusti
AU  - Cantos Sanchez de Ibargüen, Blanca
AU  - Delgado Mingorance, Juan Ignacio
AU  - Bellet Ezquerra, Meritxell
AU  - de Casa, Sonia
AU  - Gimeno, Asuncion
AU  - Martin, Miguel
PY  - 2022
DO  - 10.1016/j.breast.2022.09.006
UR  - http://hdl.handle.net/10668/22065
T2  - Breast (Edinburgh, Scotland)
AB  - Breast cancer is the most common malignancy and the second leading cause of cancer-related mortality in Spanish women. Ribociclib in combination with endocrine therapy (ET) has shown superiority in prolonging survival in patients with hormone...
LA  - en
KW  - Advanced breast cancer
KW  - CDK4/6 inhibitor
KW  - Postmenopausal
KW  - Premenopausal
KW  - Ribociclib
KW  - Área de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de Cádiz
KW  - Humans
KW  - Female
KW  - Middle Aged
KW  - Breast Neoplasms
KW  - Letrozole
KW  - Receptor, ErbB-2
KW  - Aminopyridines
KW  - Aromatase Inhibitors
KW  - Protein Kinase Inhibitors
KW  - Neutropenia
KW  - Antineoplastic Combined Chemotherapy Protocols
TI  - Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial.
TY  - research article
VL  - 66
ER  -